208 related articles for article (PubMed ID: 2138364)
21. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
22. Immunoassay of human platelet factor 4(PF4, antiheparin factor) by radial immunodiffusion.
Niewiarowski S; Lowery CT; Hawiger J; Millman M; Timmons S
J Lab Clin Med; 1976 Apr; 87(4):720-33. PubMed ID: 818325
[TBL] [Abstract][Full Text] [Related]
23. Beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) release by adenosine diphosphate (ADP) contact with native whole blood.
Pengo V; Boschello M; Prandoni P; Schivazappa L; Girolami A
Thromb Res; 1985 Sep; 39(5):645-50. PubMed ID: 2417360
[No Abstract] [Full Text] [Related]
24. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.
Cella G; Colby SI; Taylor AD; McCracken L; Parisi AF; Sasahara AA
Thromb Res; 1983 Mar; 29(5):499-509. PubMed ID: 6222505
[TBL] [Abstract][Full Text] [Related]
25. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
Tripodi A; Moia M; Bottasso B; Tenconi PM; Gianese F; Mannucci PM
Thromb Res; 1991 Jun; 62(6):663-72. PubMed ID: 1926059
[TBL] [Abstract][Full Text] [Related]
26. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans.
Dol F; Houin G; Rostin M; Montastruc JL; Dupouy D; Gianese F; Sie P; Boneu B
Blood; 1989 Oct; 74(5):1577-82. PubMed ID: 2790187
[TBL] [Abstract][Full Text] [Related]
28. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Tollefsen DM; Pestka CA
J Clin Invest; 1985 Feb; 75(2):496-501. PubMed ID: 3838317
[TBL] [Abstract][Full Text] [Related]
29. Influence of urapidil on in vitro platelet response to adrenaline and other aggregating agents.
Emanuelli G; Anfossi G; Lanzio M; Mularoni E; Calcamuggi G; Brunello F; Busca GP; Ciani D
Pharmacol Res Commun; 1988 Oct; 20(10):883-99. PubMed ID: 2976942
[TBL] [Abstract][Full Text] [Related]
30. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
Merton RE; Thomas DP
Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
[TBL] [Abstract][Full Text] [Related]
31. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
32. [Dermatan sulfate and the prevention of experimental venous thrombosis].
Desnoyers P; Bara L; Samama M
Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
[TBL] [Abstract][Full Text] [Related]
33. The effect of platelet factor 4 (PF4) on assays of plasma heparin.
Levine SP; Sorenson RR; Harris MA; Knieriem LK
Br J Haematol; 1984 Aug; 57(4):585-96. PubMed ID: 6743573
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of Acanthopanax gracilistylus saponins on human platelet aggregation and platelet factor 4 liberation in vitro.
Chen XC; Xia L; Hu S; Huang G
Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):523-6. PubMed ID: 9863147
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of platelet function by polymorphonuclear leukocytes.
Zatta A; Prosdocimi M; Bertelé V; Bazzoni G; Del Maschio A
J Lab Clin Med; 1990 Nov; 116(5):651-60. PubMed ID: 2146349
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway.
Sturk A; Asyee GM; Schaap MC; van Maanen M; ten Cate JW
Thromb Res; 1985 Nov; 40(3):359-72. PubMed ID: 2934863
[TBL] [Abstract][Full Text] [Related]
37. Activation of heparin cofactor II by heparin and dermatan sulfate.
Tollefsen DM
Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014
[TBL] [Abstract][Full Text] [Related]
38. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
Messmore HL; Griffin B; Fareed J; Coyne E; Seghatchian J
Ann N Y Acad Sci; 1989; 556():217-32. PubMed ID: 2472085
[TBL] [Abstract][Full Text] [Related]
39. Highly sulfated dermatan sulfate from the skin of the ray Raja montagui: anticoagulant activity and mechanism of action.
Ben Mansour M; Dhahri M; Hassine M; Ajzenberg N; Venisse L; Ollivier V; Chaubet F; Jandrot-Perrus M; Maaroufi RM
Comp Biochem Physiol B Biochem Mol Biol; 2010 Jul; 156(3):206-15. PubMed ID: 20363356
[TBL] [Abstract][Full Text] [Related]
40. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Sudo T; Ito H; Ozeki Y; Kimura Y
Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
